Feeds:
Posts
Comments

Posts Tagged ‘facet’

*****

TODAY’S NEWS

Botox heading to an arm near you – The Food and Drug Administration said Tuesday it approved Allergan‘s botulinum-based drug Botox to treat spasms of the elbow, wrist and fingersmore

Abbott to boost pipeline with Facet buy – Abbott says the acquisition will boost its early- and mid-stage pharmaceutical pipeline. The developer has its eyes on two primary therapeutic areas–immunology and oncology. The highest-priority program is daclizumab, a Phase II biologic for multiple sclerosis that will move into Phase III trials in Q2 of 2010. Facet is already partnered with Biogen Idec on the compound. The biotech also has oncology compounds for multiple myeloma and chronic lymphocytic leukemia in early to mid-stage trialsmore

FDA panel gives (preliminary) green light to InterMune’s lung drug.

Jury verdict against Novartis for rep who claimed retaliation after taking maternity leave.

RECOMMENDED

Curriculum Design – Sometimes you need a point solution – and sometimes you need a new strategic direction for your training curriculum. Not to worry – we’ve got the partners you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

More docs using e-Prescribing. Look for this to keep accelerating.

JUST FOR FUN

Eye-catching examples of urban decay photography. More interesting than it sounds!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

***

Read Full Post »